|
Mouse
Index >> Targeted Mutagenesis Resources Bay Genomics The major goal of BayGenomics is to identify genes relevant to cardiovascular and pulmonary disease. We are using gene-trap vectors to inactivate thousands of genes in mouse embryonic stem (ES) cells for the purpose of generating knockout mice. We make all of our ES cell lines readily available to the scientific research community. Fred
Hutchison Cancer Research Center German
Gene Trap Consortium Manitoba
Institute of Cell Biology, Centre for Mammalian Functional Genomics Gene
trap Consortium Centre
For Modelling Human Disease Gene Trap Core, University of Toronto/Mount
Sinai Hospital Induced
Mutant Resource Lexicon Genetics Corp. Lexicon Genetics is a biopharmaceutical company focused on the discovery of breakthrough treatments for human disease. We use proprietary gene knockout technology to systematically discover the physiological functions of genes in mice and to identify which corresponding human genes encode potential targets for therapeutic intervention, or drug targets. Deltagen Deltagen's unique systems biology approach is designed to help clear the first and major hurdle of drug target discovery: lead validation. Our high-throughput in vivo mammalian knockout technology , systematic array analysis and cell-based array analysis capabilities enable us to identify and validate the utility of genomic targets within a living model at an extraordinary scale and speed Velocigene/Regeneron Mouse Knockout & Mutation Database Fully searchable database of phenotypic information related to knockouts and classical mutations in mice , includingextensive links to MEDLINE on BioMedNet Deltabase DeltaBase is a comprehensive, fully featured searchable database of in vivo -derived mammalian gene function information and gene targets. Built upon our high-throughput mouse gene knockout technology and standardized phenotypic analysis protocols, this cutting-edge tool can be used in the pharmaceutical and biotechnology industries to identify drug targets, validate the therapeutic potential of specific genes and accelerate the drug discovery process. DeltaBase currently is licensed by nonexclusive agreement to such leading global pharmaceutical companies as Pfizer, GlaxoSmithKline and Merck. |
||||||||
| Any questions
or concerns regarding the genetics programs please contact Jonathan D.
Pollock Ph.D. (301) 443-1887 or jp183r@nih.gov |
||||||||
NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment
|